<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840264</url>
  </required_header>
  <id_info>
    <org_study_id>SAHMO204</org_study_id>
    <nct_id>NCT04840264</nct_id>
  </id_info>
  <brief_title>Docetaxel, Oxaliplatin and 5-FU in Metastatic Gastric Adenocarcinoma With Inoperable Malignant Bowel Obstruction</brief_title>
  <official_title>A Phase II, Non-Randomized, Multi-Cohort Trial of Docetaxel, Oxaliplatin and 5-Fluorouracil in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Inoperable Malignant Bowel Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of docetaxel, oxaliplatin and 5-Fluorouracil for advanced gastric or&#xD;
      gastroesophageal junction adenocarcinoma with inoperable malignant bowel obstruction: the&#xD;
      triplet regimen will be given as 1st, 2nd or 3rd line treatment to participants. The primary&#xD;
      study hypothesis is that the regimen will provide a clinically meaningful Bowel Obstruction&#xD;
      Remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label non-randomization trail. The study will have 3 cohorts. Cohorts 1 to 3&#xD;
      will run simultaneously. In Cohort 1, participants who have received at least two prior&#xD;
      therapies for their advanced disease will receive the experimental regimen. In Cohort 2,&#xD;
      participants who have received only one previous therapy for their disease will receive the&#xD;
      same regimen. In Cohort 3, participants who have not received any previous therapy will&#xD;
      receive the triplet combination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Obstruction Clearance disease control response</measure>
    <time_frame>30 days</time_frame>
    <description>Proportion of patients with Obstruction Clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Obstruction Clearance</measure>
    <time_frame>30 days</time_frame>
    <description>From recruitment to obstruction clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strangulation</measure>
    <time_frame>30 days</time_frame>
    <description>Proportion of patients with strangulated bowel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>From recruitment to death or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessed by EORTC C-30</measure>
    <time_frame>3 years</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) C-30 questionaire is a general patient self-evaluation of subjective quality life status. The score of this questionnaire ranges between 0 and 30. The higher score indicates the worse quality of life</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Metastatic Gastric Adenocarcinoma</condition>
  <condition>Metastatic Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>3rd Line Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 25mg/m, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85mg/m, ivdrip 180 min, D1, D15; 5Fu 1200mg/m, civ 24 hours, D1, D8, D15 Repeat every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd Line Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 25mg/m, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85mg/m, ivdrip 180 min, D1, D15; 5Fu 1200mg/m, civ 24 hours, D1, D8, D15 Repeat every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1st Line Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 25mg/m, ivdrip 60 min, D1, D8, D15; Oxaliplatin 85mg/m, ivdrip 180 min, D1, D15; 5Fu 1200mg/m, civ 24 hours, D1, D8, D15 Repeat every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>25 mg/m, D1, D8, D15, repeat every 4 weeks.</description>
    <arm_group_label>1st Line Therapy</arm_group_label>
    <arm_group_label>2nd Line Therapy</arm_group_label>
    <arm_group_label>3rd Line Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85 mg/m, , D1, D15, repeat every 4 weeks.</description>
    <arm_group_label>1st Line Therapy</arm_group_label>
    <arm_group_label>2nd Line Therapy</arm_group_label>
    <arm_group_label>3rd Line Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5Fluorouracil</intervention_name>
    <description>1200 mg/m, D1, D8, D15, repeat every 4 weeks.</description>
    <arm_group_label>1st Line Therapy</arm_group_label>
    <arm_group_label>2nd Line Therapy</arm_group_label>
    <arm_group_label>3rd Line Therapy</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years of age;&#xD;
&#xD;
          -  Diagnosis of bowel obstruction secondary to gastric or Gastroesophageal Junction&#xD;
             adenocarcinoma caused either by tumor itself or adhesions in the setting of active&#xD;
             malignancy;&#xD;
&#xD;
          -  Cross-sectional imaging performed within 7 days of clinical symptoms of bowel&#xD;
             obstruction (nausea, vomiting, and constipation ± abdominal pain);&#xD;
&#xD;
          -  Patient must be considered as inoperable MBO by a surgical consultant;&#xD;
&#xD;
          -  Written informed consent form patients;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bacteremia/septicemia with a documented positive blood culture;&#xD;
&#xD;
          -  Patients already received the same regimen prior to study enrollment;&#xD;
&#xD;
          -  Patients undergoing bowel surgery or stent placement for the obstruction;&#xD;
&#xD;
          -  Those patients complicated with incarcerated hernia;&#xD;
&#xD;
          -  Pregnant or nursing female participants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Xiao, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Sixth Affiliated hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Xiao, PhD</last_name>
    <phone>13711114566</phone>
    <email>Xiaoj26@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Sixth Affiliated hosipital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jian Xiao, PhD</last_name>
      <phone>13711114566</phone>
      <email>Xiaoj26@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 18, 2021</last_update_submitted>
  <last_update_submitted_qc>April 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jian Xiao</investigator_full_name>
    <investigator_title>Asso Professor</investigator_title>
  </responsible_party>
  <keyword>Bowel Obstruction, Docetaxel, Oxaliplatin, 5-Fluorouracil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Intestinal Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

